<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effects of interleukin 12 (IL-12) on natural killer (NK) cell cytotoxicity and on the production of interferon-gamma (IFN-gamma) and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha (TNF-alpha) were examined in 15 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), which are well known to have immunologic defects, and in 11 <z:mpath ids='MPATH_458'>normal</z:mpath> subjects </plain></SENT>
<SENT sid="1" pm="."><plain>The NK cell cytotoxicity of <z:hpo ids='HP_0000001'>all</z:hpo> of the <z:mpath ids='MPATH_458'>normal</z:mpath> subjects was augmented by incubation with IL-12 alone, and co-incubation with interleukin 2 (IL-2) further augmented it (type A response) </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients showed varied responses to IL-12/IL-2 </plain></SENT>
<SENT sid="3" pm="."><plain>Seven patients showed the type A response, resulting in augmented NK cell cytotoxicity which was similar to that in the <z:mpath ids='MPATH_458'>normal</z:mpath> subjects </plain></SENT>
<SENT sid="4" pm="."><plain>In five other patients the cytotoxicity was not increased by IL-12 alone, but the combination of IL-12 and IL-2 did augment the cytotoxicity (type B response) </plain></SENT>
<SENT sid="5" pm="."><plain>The augmented cytotoxicity in these type B patients was lower than that in the <z:mpath ids='MPATH_458'>normal</z:mpath> subjects </plain></SENT>
<SENT sid="6" pm="."><plain>In the final three <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients the cytotoxicity was low and not affected by IL-12 and/or IL-2 (type C response) </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients with refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) and patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation showed a type B or C response </plain></SENT>
<SENT sid="8" pm="."><plain>Conversely, six of eight refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> patients showed a type A response </plain></SENT>
<SENT sid="9" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients there was a positive correlation between the percentage of CD3- CD56+ cells in pre-incubated cells and the cytotoxicity of cells incubated with IL-12/IL-2 </plain></SENT>
<SENT sid="10" pm="."><plain>The combination of IL-12 and IL-2 augmented IFN-gamma and TNF-alpha production by nonadherent mononuclear cells in a synergistic or cumulative manner, respectively, in most patients </plain></SENT>
<SENT sid="11" pm="."><plain>These results suggest that IL-12, alone or with IL-2, may modulate these important immunologic functions in most <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
</text></document>